Hepatitis C Virus Recurrence in patients underwent Living Donor Liver Transplantation: efficacy and safety of treatment with combined Sofosbuvir and Daclatasvir

Abstract

- Multiple all-oral regimens with improved tolerability have achieved rates of sustained virologic response (SVR) exceeding 90% (Feld et al., 2014). - The safety and efficacy profile of these DAA combinations is particularly relevant in those with HCV recurrence after liver transplantation (LT) (Lens et al., 2014). - The pan-genotypic combination of daclatasvir and sofosbuvir, with or without ribavirin, has achieved high SVR rates (Nelson et al., 2015). - Daclatasvir is an inhibitor of the HCV NS5A replication complex; sofosbuvir is a nucleotide inhibitor of the HCV NS5B polymerase (Gao et al., 2010). - Both have favorable safety profiles and are dosed once daily, with few clinically significant drug-drug interactions, including a lack of interactions with cyclosporine or tacrolimus(Bifano et al., 2015)